{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:43:46Z","timestamp":1785833026188,"version":"3.56.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Scientific Research C","award":["17K11384"],"award-info":[{"award-number":["17K11384"]}]},{"name":"Scientific Research C","award":["23K08963"],"award-info":[{"award-number":["23K08963"]}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology, Japan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Salivary gland cancer (SGC) is rare and has various histological types. This rarity and heterogeneity have hindered elucidation of the therapeutic contribution of systemic therapy, including immune checkpoint inhibitors, to recurrent or metastatic SGC (RM-SGC). The purpose of this trial was to investigate the efficacy and safety of nivolumab for platinum-refractory RM-SGC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase II trial for platinum-refractory RM-SGC was conducted at nine centers. Nivolumab 240\u00a0mg was administered intravenously every 2\u00a0weeks. The primary endpoint was the objective response rate (ORR), and secondary endpoints were disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-four patients were enrolled between March 2018 and January 2022. The main histological types were salivary duct carcinoma (n =\u00a010), adenoid cystic carcinoma (n =\u00a06), and adenocarcinoma not otherwise specified (n =\u00a05). The ORR was 8.3% (2\/24, 80% CI, 2.2\u201320.6), with two partial responses in patients with salivary duct carcinoma. The DCR was 29.2% (7\/24), while all of the other 17 patients (70.8%) showed progressive disease on first disease evaluation at 12\u00a0weeks. With a median follow-up of 21.2\u00a0months, median PFS and OS were 3.0\u00a0months (95% CI, 2.8\u20133.2) and 25.0\u00a0months (95% CI, 10.9\u201339.1), respectively. There were no new safety concerns with nivolumab monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This phase II trial of nivolumab for patients with platinum-refractory RM-SGC did not meet its primary endpoint of ORR. Although nivolumab may be worth further development in salivary duct carcinoma, these results may raise concerns over nivolumab monotherapy for RM-SGC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyaf192","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T13:07:05Z","timestamp":1763039225000},"page":"274-281","source":"Crossref","is-referenced-by-count":2,"title":["A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6153-6456","authenticated-orcid":false,"given":"Yoshiaki","family":"Nagatani","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Hematology, Kobe University Hospital , 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8021-6116","authenticated-orcid":false,"given":"Naomi","family":"Kiyota","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Kobe University Hospital , 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017 ,","place":["Japan"]},{"name":"Kobe University Hospital Cancer Center , 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology, Miyagi Cancer Center , 47-1 Nodayama, Medeshimashiode, Natori, Miyagi 981-1293 ,","place":["Japan"]},{"name":"Department of Head and Neck Oncology Division, Saitama Medical University International Medical Center , 1397-1, Yamane, Hidaka, Saitama 350-1298 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Asada","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Miyagi Cancer Center , 47-1 Nodayama, Medeshimashiode, Natori, Miyagi 981-1293 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Higashino","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Osaka Medical and Pharmaceutical University , 2-7 Daigaku-machi, Takatsuki 569-8686 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7629-6803","authenticated-orcid":false,"given":"Hironaga","family":"Satake","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kochi Medical School , Kohasu, Oko-Cho, Nankoku, Kochi 783-8505 ,","place":["Japan"]},{"name":"Cancer Treatment Center, Kansai Medical University Hospital , 2-3-1 Shinmachi, Hirakata, Osaka 573-1191 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogen","family":"Boku","sequence":"additional","affiliation":[{"name":"Cancer Treatment Center, Kansai Medical University Hospital , 2-3-1 Shinmachi, Hirakata, Osaka 573-1191 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2014Head and Neck Surgery, Nara Medical University , 840 Shijo-cho, Kashihara, Nara 634-8522 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7502-3619","authenticated-orcid":false,"given":"Hirokazu","family":"Uemura","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2014Head and Neck Surgery, Nara Medical University , 840 Shijo-cho, Kashihara, Nara 634-8522 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Ota","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2014Head and Neck Surgery, Kindai University Nara Hospital , 1248-1 Otoda-cho, Ikoma, Nara 630-0293 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunari","family":"Yane","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2014Head and Neck Surgery, Kindai University Nara Hospital , 1248-1 Otoda-cho, Ikoma, Nara 630-0293 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kindai University Faculty of Medicine , 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Onoe","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hyogo Cancer Center , 13-70, Kitaouji-cho, Akashi, Hyogo 673-8588 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Hirayama","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Hyogo Cancer Center , 13-70, Kitaouji-cho, Akashi, Hyogo 673-8588 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Tsujikawa","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2014Head and Neck Surgery, Kyoto Prefectural University of Medicine , 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology\u2014Head and Neck Surgery, Kobe University Graduate School of Medicine , 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikari","family":"Shimoda","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology\u2014Head and Neck Surgery, Kobe University Graduate School of Medicine , 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-Ichi","family":"Nibu","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology\u2014Head and Neck Surgery, Kobe University Graduate School of Medicine , 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Imamura","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Kobe University Hospital , 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Kimbara","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Kobe University Hospital , 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Koyama","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Kobe University Hospital , 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7793-5013","authenticated-orcid":false,"given":"Yohei","family":"Funakoshi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Kobe University Hospital , 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Kobe University Hospital , 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017 ,","place":["Japan"]},{"name":"Kobe University Hospital Cancer Center , 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"2026031310020764700_ref1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12105-022-01420-1","article-title":"Update from the 5th edition of the World Health Organization classification of head and neck Tumors. Salivary glands","volume":"16","author":"Sk\u00e1lov\u00e1","year":"2022","journal-title":"Head Neck Pathol"},{"key":"2026031310020764700_ref2","year":"2020"},{"key":"2026031310020764700_ref3","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/annonc\/mdx771","article-title":"A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma","volume":"29","author":"Fushimi","year":"2018","journal-title":"Ann Oncol"},{"key":"2026031310020764700_ref4","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1200\/JCO.21.00468","article-title":"Abiraterone acetate in patients with castration-resistant, androgen receptor-expressing salivary gland cancer: A phase II trial","volume":"39","author":"Locati","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026031310020764700_ref5","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1200\/JCO.22.00229","article-title":"Phase II study of enzalutamide for patients with androgen receptor-positive salivary gland cancers (alliance A091404)","volume":"40","author":"Ho","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026031310020764700_ref6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026031310020764700_ref7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.annonc.2019.11.018","article-title":"Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: Results from MyPathway, a phase IIa multiple basket study","volume":"31","author":"Kurzrock","year":"2020","journal-title":"Ann Oncol"},{"key":"2026031310020764700_ref8","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1097\/PAS.0000000000000980","article-title":"The role of molecular testing in the differential diagnosis of salivary gland carcinomas","volume":"42","author":"Sk\u00e1lov\u00e1","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"2026031310020764700_ref9","doi-asserted-by":"publisher","first-page":"e779","DOI":"10.1093\/oncolo\/oyac080","article-title":"Larotrectinib treatment for patients with TRK fusion-positive salivary gland cancers","volume":"29","author":"Le","year":"2022","journal-title":"Oncologist"},{"key":"2026031310020764700_ref10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/hed.23577","article-title":"Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck","volume":"37","author":"Thomson","year":"2015","journal-title":"Head Neck"},{"key":"2026031310020764700_ref11","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1093\/annonc\/mdw287","article-title":"A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma","volume":"27","author":"Ho","year":"2016","journal-title":"Ann Oncol"},{"key":"2026031310020764700_ref12","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1200\/JCO.18.01859","article-title":"Phase II study of Lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma","volume":"37","author":"Tchekmedyian","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026031310020764700_ref13","doi-asserted-by":"publisher","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-21-1061","article-title":"Randomized phase II study of Axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma","volume":"27","author":"Kang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026031310020764700_ref14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2026031310020764700_ref15","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"2026031310020764700_ref16","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"2026031310020764700_ref17","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026031310020764700_ref18","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"2026031310020764700_ref19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced Esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"2026031310020764700_ref20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"2026031310020764700_ref21","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1200\/JCO.2019.37.15_suppl.6083","article-title":"NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent\/metastatic (R\/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group","volume":"37","author":"Fayette","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026031310020764700_ref22","doi-asserted-by":"publisher","first-page":"6084","DOI":"10.1200\/JCO.2019.37.15_suppl.6084","article-title":"A phase II trial cohort of nivolumab plus ipilimumab in patients (pts) with recurrent\/metastatic adenoid cystic carcinoma (R\/M ACC)","volume":"37","author":"Tchekmedyian","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026031310020764700_ref23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ejca.2022.05.007","article-title":"Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study","volume":"171","author":"Even","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026031310020764700_ref24","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1038\/s41591-023-02518-x","article-title":"Nivolumab plus ipilimumab in advanced salivary gland cancer: A phase 2 trial","volume":"29","author":"Vos","year":"2023","journal-title":"Nat Med"},{"key":"2026031310020764700_ref25","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"2026031310020764700_ref26","doi-asserted-by":"publisher","first-page":"16988","DOI":"10.1038\/s41598-020-73965-6","article-title":"Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma","volume":"10","author":"Niwa","year":"2020","journal-title":"Sci Rep"},{"key":"2026031310020764700_ref27","doi-asserted-by":"publisher","first-page":"981","DOI":"10.21873\/anticanres.15558","article-title":"Treatment efficacy of PD-1 inhibitor therapy in patients with recurrent and\/or metastatic salivary gland carcinoma","volume":"42","author":"Hashimoto","year":"2022","journal-title":"Anticancer Res"},{"key":"2026031310020764700_ref28","doi-asserted-by":"publisher","first-page":"e002591","DOI":"10.1136\/jitc-2021-002591","article-title":"Mechanisms of regulatory T cell infiltration in tumors: Implications for innovative immune precision therapies","volume":"9","author":"Nishikawa","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026031310020764700_ref29","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp Mol Med"},{"key":"2026031310020764700_ref30","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1158\/0008-5472.CAN-12-4354","article-title":"Vascular normalization as an emerging strategy to enhance cancer immunotherapy","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res"},{"key":"2026031310020764700_ref31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3892\/or.2021.8247","article-title":"Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1low and immune desert-like mouse tumors","volume":"47","author":"Ishikura","year":"2022","journal-title":"Oncol Rep"},{"key":"2026031310020764700_ref32","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"2026031310020764700_ref33","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"2026031310020764700_ref34","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or Everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"2026031310020764700_ref35","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"key":"2026031310020764700_ref36","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/ajco.14108","article-title":"Different characteristics of the tumor immune microenvironment among subtypes of salivary gland cancer","volume":"20","author":"Nagatani","year":"2024","journal-title":"Asia Pac J Clin Oncol"},{"key":"2026031310020764700_ref37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1158\/2159-8290.CD-19-0790","article-title":"Directing traffic: How to effectively drive T cells into Tumors et\u00a0al.","volume":"10","author":"Anandappa","year":"2020","journal-title":"Cancer Discov"},{"key":"2026031310020764700_ref38","doi-asserted-by":"publisher","first-page":"e1397","DOI":"10.1002\/cti2.1397","article-title":"Understanding the tumor microenvironment in head and neck squamous cell carcinoma","volume":"11","author":"Rad","year":"2022","journal-title":"Clin Transl Immunology"},{"key":"2026031310020764700_ref39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41698-024-00501-4","article-title":"Immunological subtyping of salivary gland cancer identifies histological origin-specific tumor immune microenvironment","volume":"8","author":"Hong","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"2026031310020764700_ref40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40425-018-0464-1","article-title":"A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer","volume":"7","author":"D'Amico","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026031310020764700_ref41","doi-asserted-by":"publisher","first-page":"e004704","DOI":"10.1136\/jitc-2022-004704","article-title":"GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies","volume":"10","author":"Pascual-Pasto","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026031310020764700_ref42","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"2026031310020764700_ref43","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s12105-021-01325-5","article-title":"Trophoblast cell surface antigen 2 (Trop-2) protein is highly expressed in salivary gland carcinomas and represents a potential therapeutic target","volume":"15","author":"Wolber","year":"2021","journal-title":"Head Neck Pathol"},{"key":"2026031310020764700_ref44","doi-asserted-by":"publisher","first-page":"S1562","DOI":"10.1016\/j.annonc.2024.10.449","article-title":"Trop-2 and Nectin-4 expression and their relationship with tumor immune microenvironment in salivary gland cancer","volume":"35","author":"Nagatani","year":"2024","journal-title":"Ann Oncol"},{"key":"2026031310020764700_ref45","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3390\/cancers12051075","article-title":"Overcoming heterogeneity of antigen expression for effective CAR T cell targeting of cancers","volume":"12","author":"Kailayangiri","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026031310020764700_ref46","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.1200\/JCO.2024.42.16_suppl.6107","article-title":"Effect of RGT-61159 on inhibition of oncogene c-MYB synthesis and tumor growth inhibition in a broad range of ACC PDX models, at well tolerated doses in rodents and non-human primates","volume":"42","author":"Simon","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026031310020764700_ref47","first-page":"S662","volume-title":"Ann Oncol.","author":"Ferrarotto","year":"2025"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/3\/274\/65739624\/hyaf192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/3\/274\/65739624\/hyaf192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:02:19Z","timestamp":1773410539000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/3\/274\/8365164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,12,4]]},"published-print":{"date-parts":[[2026,3,13]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf192","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,12,4]]}}}